MARY WISE: Open Payments
NPI 1558502153 · MILWAUKEE, WI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$590 in 14 payments from 8 companies in 2025. Trend: 2023 $0 · 2024 $135 · 2025 $590
Food & beverage: $590
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 4 | $177 |
| Neurocrine BioSciences, Inc. | 2 | $128 |
| Gilead Sciences, Inc. | 1 | $107 |
| Vanda Pharmaceuticals Inc. | 2 | $52 |
| Otsuka America Pharmaceutical, Inc. | 2 | $47 |
| Alkermes, Inc. | 1 | $34 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $23 |
| Lundbeck LLC | 1 | $22 |
Products named: AUSTEDO XR, INGREZZA, Epclusa, REXULTI, FANAPT, ARISTADA, CAPLYTA.
Industry payments across WI — which companies pay providers there.
